These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 18516705)
1. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma. Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705 [TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Pavone L; Andrulli S; Santi R; Majori M; Buzio C Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029 [TBL] [Abstract][Full Text] [Related]
3. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2. Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981 [TBL] [Abstract][Full Text] [Related]
9. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Hänninen EL; Körfer A; Hadam M; Schneekloth C; Dallmann I; Menzel T; Kirchner H; Poliwoda H; Atzpodien J Cancer Res; 1991 Dec; 51(23 Pt 1):6312-6. PubMed ID: 1933892 [TBL] [Abstract][Full Text] [Related]
10. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial. Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346 [TBL] [Abstract][Full Text] [Related]
11. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Buzio C; Andrulli S; Santi R; Pavone L; Passalacqua R; Potenzoni D; Ferrozzi F; Giacosa R; Vaglio A Cancer; 2001 Nov; 92(9):2286-96. PubMed ID: 11745283 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience. Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898 [TBL] [Abstract][Full Text] [Related]
13. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells. Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954 [TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy. Olencki T; Finke J; Tubbs R; Tuason L; Greene T; McLain D; Swanson SJ; Herzog P; Stanley J; Edinger M; Budd GT; Bukowski RM J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):69-80. PubMed ID: 8859726 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059 [TBL] [Abstract][Full Text] [Related]
16. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2. Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906 [TBL] [Abstract][Full Text] [Related]
17. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients. Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981 [TBL] [Abstract][Full Text] [Related]
18. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698 [TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. Göhring B; Riemann D; Rebmann U; Heynemann H; Schabel J; Langner J Urol Res; 1996; 24(5):297-303. PubMed ID: 8931295 [TBL] [Abstract][Full Text] [Related]
20. In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2. Schomburg A; Menzel T; Körfer A; Heer G; Dallmann I; Kirchner H; Poliwoda H; Atzpodien J Nat Immun; 1992; 11(3):133-43. PubMed ID: 1392401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]